Journal of long-term effects of medical implants
Design considerations in penile prostheses: the American Medical Systems product line. J Long Term Eff Med Implants. 1997; 7(1):55-64.
Design considerations in penile prostheses: the American Medical Systems product line.
Miner M, Morgentaler A, Khera M, Traish AM
The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk. Clin Endocrinol (Oxf). 2018 07; 89(1):3-10.
The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk.
Rubenstein SC, Green LS, Schopperle WM, DeWolf WC, Morgentaler A
Temperature-dependent expression of a 95 kD protein in rat testis. Andrologia. 1995 Mar-Apr; 27(2):107-13.
Temperature-dependent expression of a 95 kD protein in rat testis.
The Journal of clinical endocrinology and metabolism
Commentary: Guideline for male testosterone therapy: a clinician's perspective. J Clin Endocrinol Metab. 2007 Feb; 92(2):416-7.
Commentary: Guideline for male testosterone therapy: a clinician's perspective.
Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80. Eur Urol. 2007 Jul; 52(1):292; author reply 293-4.
Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80.
The effect of aging on spermatogenesis and pregnancy outcomes. Urol Clin North Am. 2008 May; 35(2):331-9, xi.
The effect of aging on spermatogenesis and pregnancy outcomes.
Rhoden EL, Gobbi D, Rhoden CR, Menti E, Roehe AN, Hartmann A, Morgentaler A
Effects of chronic administration of dehydroepiandrosterone on serum testosterone levels and prostatic tissue in rats. J Urol. 2003 Nov; 170(5):2101-3.
Effects of chronic administration of dehydroepiandrosterone on serum testosterone levels and prostatic tissue in rats.
Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003 Dec; 170(6 Pt 1):2348-51.
Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
The History of Testosterone and the Evolution of its Therapeutic Potential. Sex Med Rev. 2020 Apr; 8(2):286-296.
The History of Testosterone and the Evolution of its Therapeutic Potential.
Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Shabsigh R, Swerdloff RS, Wang C
Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. J Urol. 2008 Dec; 180(6):2307-13.
Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
Classics of urology: a half century history of the most frequently cited articles (1955-2009). Urology. 2010 Jun; 75(6):1261-8.
Classics of urology: a half century history of the most frequently cited articles (1955-2009).
Morgentaler A, Rhoden EL, Guay A, Traish A
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010 Mar; 105(6):884-5; author reply 885-6.
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.
Lazarou S, Reyes-Vallejo L, Morgentaler A
Technical advances in penile prostheses. J Long Term Eff Med Implants. 2006; 16(3):235-47.
Technical advances in penile prostheses.
Morgentaler A, Belville JS, Tumeh SS, Richie JP, Loughlin KR
Rational approach to evaluation and management of spontaneous perirenal hemorrhage. Surg Gynecol Obstet. 1990 Feb; 170(2):121-5.
Rational approach to evaluation and management of spontaneous perirenal hemorrhage.
Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy. J Sex Med. 2011 Dec; 8(12):3465-70.
Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy.
Traish AM, Miner MM, Morgentaler A, Zitzmann M
Testosterone deficiency. Am J Med. 2011 Jul; 124(7):578-87.
Reyes-Vallejo L, Lazarou S, Morgentaler A
Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J Sex Med. 2007 Nov; 4(6):1757-62.
Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006 Dec; 68(6):1263-7.
Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A
The association of time of day and serum testosterone concentration in a large screening population. BJU Int. 2007 Sep; 100(3):509-13.
The association of time of day and serum testosterone concentration in a large screening population.
Hyponatremic encephalopathy after endometrial ablation. JAMA. 1994 Feb 02; 271(5):344; author reply 345.
Hyponatremic encephalopathy after endometrial ablation.
Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D, Khera M
Testosterone therapy in men with untreated prostate cancer. J Urol. 2011 Apr; 185(4):1256-60.
Testosterone therapy in men with untreated prostate cancer.
Y chromosome microdeletions and male infertility: who should be tested and why? BJU Int. 2006 Mar; 97(3):441-3.
Y chromosome microdeletions and male infertility: who should be tested and why?
Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol. 2007 Sep; 52(3):623-5.
Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship.
Vasectomy and increased risk of prostate cancer. JAMA. 1993 Aug 11; 270(6):705-6; author reply 708.
Vasectomy and increased risk of prostate cancer.
Traish AM, Krakowsky Y, Doros G, Morgentaler A
Do 5a-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sex Med Rev. 2019 01; 7(1):95-114.
Do 5a-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results.
Detached ciliary tufts in the epididymis: a lesson in applied anatomy. Urology. 1995 Nov; 46(5):740-2.
Detached ciliary tufts in the epididymis: a lesson in applied anatomy.
Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C
Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009 Jul; 56(1):48-56.
Testosterone and prostate cancer: revisiting old paradigms.
Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int. 2012 Dec; 110(11 Pt B):E547.
Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
Testosterone therapy and medical hysteria. Nat Rev Urol. 2018 Nov; 15(11):659-660.
Testosterone therapy and medical hysteria.
Morgentaler A, Fung MY, Harris DH, Powers RD, Alper MM
Sperm morphology and in vitro fertilization outcome: a direct comparison of World Health Organization and strict criteria methodologies. Fertil Steril. 1995 Dec; 64(6):1177-82.
Sperm morphology and in vitro fertilization outcome: a direct comparison of World Health Organization and strict criteria methodologies.
Penile mass caused by the newly described organism Mycobacterium celatum. Urology. 1996 Feb; 47(2):266-8.
Penile mass caused by the newly described organism Mycobacterium celatum.
Belville JS, Morgentaler A, Loughlin KR, Tumeh SS
Spontaneous perinephric and subcapsular renal hemorrhage: evaluation with CT, US, and angiography. Radiology. 1989 Sep; 172(3):733-8.
Spontaneous perinephric and subcapsular renal hemorrhage: evaluation with CT, US, and angiography.
Current Diagnostic Criteria for Testosterone Deficiency Are Inadequate. Eur Urol Focus. 2018 04; 4(3):348-350.
Current Diagnostic Criteria for Testosterone Deficiency Are Inadequate.
Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2013 Jan; 189(1 Suppl):S26-33.
Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Nerve growth factor as a new treatment for testosterone deficiency? EBioMedicine. 2018 10; 36:10-11.
Nerve growth factor as a new treatment for testosterone deficiency?
Morrell JI, Crews D, Ballin A, Morgentaler A, Pfaff DW
3H-estradiol, 3H-testosterone and 3H-dihydrotestosterone localization in the brain of the lizard Anolis carolinensis: an autoradiographic study. J Comp Neurol. 1979 Nov 15; 188(2):201-23.
3H-estradiol, 3H-testosterone and 3H-dihydrotestosterone localization in the brain of the lizard Anolis carolinensis: an autoradiographic study.
International journal of impotence research
Response to: Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008 May-Jun; 20(3):331; author reply 332.
Response to: Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Re: effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Eur Urol. 2008 May; 53(5):1084.
Re: effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.
Ureteral pseudodiverticulosis: the case for the retrograde urogram. Urology. 1996 Jun; 47(6):924-7.
Ureteral pseudodiverticulosis: the case for the retrograde urogram.
Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population. J Sex Med. 2010 May; 7(5):1948-53.
Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population.
Testosterone and prostate cancer: what are the risks for middle-aged men? Urol Clin North Am. 2011 May; 38(2):119-24.
Testosterone and prostate cancer: what are the risks for middle-aged men?
Re: Unilateral unitary inflatable penile prosthesis to correct impaired tumescence and severe penile deformity resulting from traumatic rupture of 1 corpus cavernosum. J Urol. 1995 Sep; 154(3):1145.
Re: Unilateral unitary inflatable penile prosthesis to correct impaired tumescence and severe penile deformity resulting from traumatic rupture of 1 corpus cavernosum.
Management of impending sterility. Lancet. 1996 May 11; 347(9011):1344.
Yin Y, Stahl BC, DeWolf WC, Morgentaler A
p53-mediated germ cell quality control in spermatogenesis. Dev Biol. 1998 Dec 01; 204(1):165-71.
p53-mediated germ cell quality control in spermatogenesis.
Spontaneous corporeal herniation of the penis: a new abnormality of the tunica albuginea? J Urol. 1995 Mar; 153(3 Pt 1):737-40.
Spontaneous corporeal herniation of the penis: a new abnormality of the tunica albuginea?
Testosterone replacement therapy and prostate risks: where's the beef? Can J Urol. 2006 Feb; 13 Suppl 1:40-3.
Testosterone replacement therapy and prostate risks: where's the beef?
A self-expanding prostatic stent for bladder outlet obstruction in high risk patients. J Urol. 1993 Nov; 150(5 Pt 2):1636-40.
A self-expanding prostatic stent for bladder outlet obstruction in high risk patients.
Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship. J Sex Med. 2009 Jun; 6(6):1729-1735.
Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship.
Goodbye androgen hypothesis, hello saturation model. Eur Urol. 2012 Nov; 62(5):765-7.
Goodbye androgen hypothesis, hello saturation model.
Traish A, Bolanos J, Nair S, Saad F, Morgentaler A
Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. J Clin Med. 2018 Dec 14; 7(12).
Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence.
Ho GT, Gardner H, DeWolf WC, Loughlin KR, Morgentaler A
Influence of testicular carcinoma on ipsilateral spermatogenesis. J Urol. 1992 Sep; 148(3):821-5.
Influence of testicular carcinoma on ipsilateral spermatogenesis.
Samoszuk M, Morgentaler A, de Groot M, van Solinge W, Li Y, Adair F, Hoefer I, Haitjema S
Association of low testosterone with changes in non-cardiovascular biomarkers in adult men. Int J Impot Res. 2020 Mar; 32(2):167-175.
Association of low testosterone with changes in non-cardiovascular biomarkers in adult men.
Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Part-time
Associate Professor of Surgery (Urology)
Morgentaler A, Traish A, Hackett G, Jones TH, Ramasamy R
Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine. Sex Med Rev. 2019 10; 7(4):636-649.
Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine.
Safety of testosterone therapy in men with prostate cancer. Expert Opin Drug Saf. 2019 Nov; 18(11):1065-1076.
Safety of testosterone therapy in men with prostate cancer.
Traish AM, Hackett G, Miner M, Morgentaler A
Cardiovascular and Cerebrovascular Safety of Testosterone Therapy. Am J Med. 2019 10; 132(10):e748.
Cardiovascular and Cerebrovascular Safety of Testosterone Therapy.
Shlykova N, Davidson E, Krakowsky Y, Bolanos J, Traish A, Morgentaler A
Absent Diurnal Variation in Serum Testosterone in Young Men with Testosterone Deficiency. J Urol. 2020 04; 203(4):817-823.
Absent Diurnal Variation in Serum Testosterone in Young Men with Testosterone Deficiency.
Successful treatment of Post-orgasmic illness syndrome with human chorionic gonadotropin. Urol Case Rep. 2020 Mar; 29:101078.
Successful treatment of Post-orgasmic illness syndrome with human chorionic gonadotropin.
A Critique of the AUA Guidelines on Testosterone Deficiency. J Sex Med. 2020 04; 17(4):561-564.
A Critique of the AUA Guidelines on Testosterone Deficiency.
Letter to the editor: Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer. Investig Clin Urol. 2020 07; 61(4):452-454.
Letter to the editor: Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer.
Grober ED, Krakowsky Y, Khera M, Holmes DT, Lee JC, Grantmyre JE, Patel P, Bebb RA, Fitzpatrick R, Campbell JD, Carrier S, Morgentaler A
Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A. Can Urol Assoc J. 2021 May; 15(5):E234-E243.
Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A.
Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, Kim NN, Kingsberg SA, Morgentaler A, Nappi RE, Park K, Stuenkel CA, Traish AM, Vignozzi L
Climacteric : the journal of the International Menopause Society
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Climacteric. 2021 12; 24(6):533-550.
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Womens Health (Larchmt). 2021 04; 30(4):474-491.
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021 05; 18(5):849-867.
Lunenfeld B, Mskhalaya G, Zitzmann M, Corona G, Arver S, Kalinchenko S, Tishova Y, Morgentaler A
The aging male : the official journal of the International Society for the Study of the Aging Male
Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021 Dec; 24(1):119-138.
Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men.
Journal of experimental zoology. Part A, Ecological and integrative physiology
How the rise of testosterone therapy in men was inspired by lizard research with David Crews. J Exp Zool A Ecol Integr Physiol. 2022 01; 337(1):103-106.
How the rise of testosterone therapy in men was inspired by lizard research with David Crews.
Editorial Comment. J Urol. 2022 05; 207(5):1028.
Twitchell DK, Christensen MB, Hackett G, Morgentaler A, Saad F, Pastuszak AW
Androgens: clinical research and therapeutics
Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review. Androg Clin Res Ther. 2022; 3(1):41-53.
Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review.
Morgentaler A, Traish A, Barua RS, Dandona P, Dhindsa S, Khera M, Saad F
Recognizing the True Value of Testosterone Therapy in Health Care. Androg Clin Res Ther. 2022; 3(1):217-223.
Recognizing the True Value of Testosterone Therapy in Health Care.
The testis, eunuchs, and testosterone: a historical review over the ages and around the world. Sex Med Rev. 2024 03 26; 12(2):199-209.
The testis, eunuchs, and testosterone: a historical review over the ages and around the world.
Khera M, Orozco Rendon D, Saffati G, Morgentaler A
Lessons learned from the TRAVERSE trial. J Sex Med. 2024 09 03; 21(9):746-748.
Lessons learned from the TRAVERSE trial.
Editorial Comment. J Urol. 2025 Jan; 213(1):33.
Morgentaler A, Dhindsa S, Dobs AS, Hackett G, Jones TH, Kloner RA, Miner M, Zitzmann M, Traish AM
Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy. Mayo Clin Proc. 2024 Nov; 99(11):1785-1801.
Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy.
O' testosterone, where is thy sting? A Urologist's reflection on testosterone and prostate cancer. EClinicalMedicine. 2025 Feb; 80:103061.
O' testosterone, where is thy sting? A Urologist's reflection on testosterone and prostate cancer.
Linares Espinós E, Martínez-Salamanca JI, Morgentaler A, Moncada I, del Portillo L, Rodríguez-Izquierdo M, Areche J, Carballido J
[Patient with testosterone deficit syndrome after radical prostatectomy]. Arch Esp Urol. 2013 Sep; 66(7):663-8.
[Patient with testosterone deficit syndrome after radical prostatectomy].
The evaluation and management of testosterone deficiency: the new frontier in urology and men's health. Curr Urol Rep. 2013 Dec; 14(6):557-64.
The evaluation and management of testosterone deficiency: the new frontier in urology and men's health.
The Journal of steroid biochemistry and molecular biology
Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5a-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013 Nov; 138:462.
Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5a-reduced metabolites in men at risk for prostate cancer.
Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Aging Male. 2013 Dec; 16(4):164-8.
Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population.
Khera M, Crawford D, Morales A, Salonia A, Morgentaler A
A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014 Jan; 65(1):115-23.
A new era of testosterone and prostate cancer: from physiology to clinical implications.
Andrology: Testosterone and cardiovascular risk--deciphering the statistics. Nat Rev Urol. 2014 Mar; 11(3):131-2.
Andrology: Testosterone and cardiovascular risk--deciphering the statistics.
Kacker R, Conners W, Zade J, Morgentaler A
Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J Urol. 2014 Apr; 191(4):1072-6.
Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility.
Death by testosterone? We think not! J Sex Med. 2014 Mar; 11(3):624-9.
Deaths and cardiovascular events in men receiving testosterone. JAMA. 2014 Mar 05; 311(9):961-2.
Deaths and cardiovascular events in men receiving testosterone.
Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male. 2014 Jun; 17(2):63-5.
Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation.
Will I have a heart attack or stroke if I take testosterone therapy? J Sex Med. 2014 Jun; 11(6):1601-2.
Will I have a heart attack or stroke if I take testosterone therapy?
Testosterone, cardiovascular risk, and hormonophobia. J Sex Med. 2014 Jun; 11(6):1362-6.
Testosterone, cardiovascular risk, and hormonophobia.
Comment on "Improving the recognition, diagnosis, and management of male testosterone deficiency across the NHS: a Delphi consensus". J Sex Med. 2025 Aug 04; 22(8):1311.
Comment on "Improving the recognition, diagnosis, and management of male testosterone deficiency across the NHS: a Delphi consensus".
Khera M, Torres LO, Grober ED, Morgentaler A, Miner M, Jones TH, Mills JN, Salonia A
Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025 Oct 04; 13(4):548-573.
Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).
Gonzalez-Carranza HR, Morgentaler A, Reyes-Vallejo LA
Testosterone threshold, assay and costs among laboratories for hypogonadism diagnosis. Transl Androl Urol. 2025 Jun 30; 14(6):1759-1764.
Testosterone threshold, assay and costs among laboratories for hypogonadism diagnosis.
TESTOSTERONE DOES NOT DRIVE PROSTATE CANCER: PRESENTING THE NEW FRAMEWORK OF ANDROGEN ADEQUACY VERSUS INADEQUACY. J Urol. 2026 Jan 13; 101097JU0000000000004936.
TESTOSTERONE DOES NOT DRIVE PROSTATE CANCER: PRESENTING THE NEW FRAMEWORK OF ANDROGEN ADEQUACY VERSUS INADEQUACY.
Clift AK, Johnson H, Huang DR, Morgentaler A
Real-World Outcomes and Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study of Over 9,000 Men. World J Mens Health. 2026 Apr; 44(2):438-450.
Real-World Outcomes and Safety of Testosterone Therapy: A Longitudinal, Retrospective Cohort Study of Over 9,000 Men.
Morgentaler A, Khera M, Maggi M, Zitzmann M
Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014 Jul; 11(7):1636-45.
Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions.
New concepts regarding testosterone and prostate cancer: a breath of fresh air. Oncology (Williston Park). 2014 May; 28(5):404-5.
New concepts regarding testosterone and prostate cancer: a breath of fresh air.
San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A
Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int. 2014 Aug; 114(2):229-35.
Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance.
Medical hypothesis: loss of the endocrine function of the prostate is important to the pathophysiology of postprostatectomy erectile dysfunction. J Sex Med. 2014 Aug; 11(8):1898-902.
Medical hypothesis: loss of the endocrine function of the prostate is important to the pathophysiology of postprostatectomy erectile dysfunction.
Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A
Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014 Jul; 114(1):125-30.
Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer.
Reply to Julia Klap and Kevin R. Loughlin's letter to the editor re: Mohit Khera, David Crawford, Alvaro Morales, Andrea Salonia, Abraham Morgentaler. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014;65:115-23. Eur Urol. 2014 Aug; 66(2):e33.
Reply to Julia Klap and Kevin R. Loughlin's letter to the editor re: Mohit Khera, David Crawford, Alvaro Morales, Andrea Salonia, Abraham Morgentaler. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014;65:115-23.
Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG
Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med. 2014 Nov; 11(11):2818-25.
Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
Zarotsky V, Huang MY, Carman W, Morgentaler A, Singhal PK, Coffin D, Jones TH
Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology. 2014 Nov; 2(6):819-34.
Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men.
Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia. 2014 Dec; 46(10):1156-60.
Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens.
Does testosterone increase the risk of a cardiovascular event? J Urol. 2014 Jul; 192(1):13-5.
Does testosterone increase the risk of a cardiovascular event?
Testosterone deficiency and cardiovascular mortality. Asian J Androl. 2015 Jan-Feb; 17(1):26-31.
Testosterone deficiency and cardiovascular mortality.
RE: Testosterone treatment is a potent tumor promoter for the rat prostate. Endocrinology. 2015 Jan; 156(1):L1-2.
RE: Testosterone treatment is a potent tumor promoter for the rat prostate.
Testosterone and cardiovascular disease--the controversy and the facts. Postgrad Med. 2015 Mar; 127(2):159-65.
Testosterone and cardiovascular disease--the controversy and the facts.
Baillargeon J, Urban RJ, Kuo YF, Holmes HM, Raji MA, Morgentaler A, Howrey BT, Lin YL, Ottenbacher KJ
Public health reports (Washington, D.C. : 1974)
Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010. Public Health Rep. 2015 Mar-Apr; 130(2):143-52.
Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010.
Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM
Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015 Feb; 90(2):224-51.
Testosterone therapy and cardiovascular risk: advances and controversies.
Kacker R, Harisaran V, Given L, Miner M, Rittmaster R, Morgentaler A
Dutasteride in men receiving testosterone therapy: a randomised, double-blind study. Andrologia. 2015 Mar; 47(2):148-52.
Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
Morgentaler A, McGettigan J, Xiang Q, Danoff TM, Gould EM
Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial. Int J Impot Res. 2015 Mar-Apr; 27(2):41-5.
Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.
Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations. Asian J Androl. 2015 Mar-Apr; 17(2):206-11.
Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations.
Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, Morgentaler A
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015 Mar; 18(1):5-15.
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.
Baillargeon J, Urban RJ, Morgentaler A, Glueck CJ, Baillargeon G, Sharma G, Kuo YF
Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy. Mayo Clin Proc. 2015 Aug; 90(8):1038-45.
Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy.
Dean JD, McMahon CG, Guay AT, Morgentaler A, Althof SE, Becher EF, Bivalacqua TJ, Burnett AL, Buvat J, El Meliegy A, Hellstrom WJ, Jannini EA, Maggi M, McCullough A, Torres LO, Zitzmann M
The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. J Sex Med. 2015 Aug; 12(8):1660-86.
The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men.
Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners WP, Sarosdy MF, Yang C, Carrion R, Lipshultz LI, Khera M
Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. J Urol. 2015 Nov; 194(5):1271-6.
Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.
The practical management of testosterone deficiency in men. Nat Rev Urol. 2015 11; 12(11):641-50.
The practical management of testosterone deficiency in men.
Morgentaler A, Zitzmann M, Traish AM, Fox A
International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic. Aging Male. 2015; 18(4):205-6.
International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic.
Paduch DA, Polzer P, Morgentaler A, Althof S, Donatucci C, Ni X, Patel AB, Basaria S
Clinical and Demographic Correlates of Ejaculatory Dysfunctions Other Than Premature Ejaculation: A Prospective, Observational Study. J Sex Med. 2015 Dec; 12(12):2276-86.
Clinical and Demographic Correlates of Ejaculatory Dysfunctions Other Than Premature Ejaculation: A Prospective, Observational Study.
Response and Rebuttal to Editorial Comment on: Clinical and Demographic Correlates of Ejaculatory Dysfunctions Other than Premature Ejaculation: A Prospective, Observational Study. J Sex Med. 2015 Dec; 12(12):2289-90.
Response and Rebuttal to Editorial Comment on: Clinical and Demographic Correlates of Ejaculatory Dysfunctions Other than Premature Ejaculation: A Prospective, Observational Study.
Kacker R, Hult M, San Francisco IF, Conners WP, Rojas PA, Dewolf WC, Morgentaler A
Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016 Jan-Feb; 18(1):16-20.
Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results.
Controversies and Advances With Testosterone Therapy: A 40-Year Perspective. Urology. 2016 Mar; 89:27-32.
Controversies and Advances With Testosterone Therapy: A 40-Year Perspective.
Testosterone Therapy and Prostate Cancer. Urol Clin North Am. 2016 May; 43(2):209-16.
Testosterone Therapy and Prostate Cancer.
Kaplan AL, Hu JC, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F
Testosterone Therapy in Men With Prostate Cancer. Eur Urol. 2016 05; 69(5):894-903.
Testosterone Therapy in Men With Prostate Cancer.
Morgentaler A, Zitzmann M, Traish AM, Fox AW, Jones TH, Maggi M, Arver S, Aversa A, Chan JC, Dobs AS, Hackett GI, Hellstrom WJ, Lim P, Lunenfeld B, Mskhalaya G, Schulman CC, Torres LO
Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. Mayo Clin Proc. 2016 07; 91(7):881-96.
Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions.
Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Pro. J Urol. 2016 Oct; 196(4):985-8.
Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Pro.
Male and Female Sexual Dysfunction in a Rapidly Changing Cultural Environment: Addressing Gender Equality versus Equivalence in the Bedroom. Sex Med Rev. 2016 04; 4(2):96-102.
Male and Female Sexual Dysfunction in a Rapidly Changing Cultural Environment: Addressing Gender Equality versus Equivalence in the Bedroom.
Khera M, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, McCullough A, Morgentaler A, Torres LO, Salonia A
Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016 12; 13(12):1787-1804.
Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Overselling hysteria: The role of the media and medical journals in promoting questionable risks-a case study of the testosterone controversy. EMBO Rep. 2017 01; 18(1):11-17.
Overselling hysteria: The role of the media and medical journals in promoting questionable risks-a case study of the testosterone controversy.
Socher SA, Yin Y, Dewolf WC, Morgentaler A
Temperature-mediated germ cell loss in the testis is associated with altered expression of the cell-cycle regulator p53. J Urol. 1997 May; 157(5):1986-9.
Temperature-mediated germ cell loss in the testis is associated with altered expression of the cell-cycle regulator p53.
Khoudary KP, DeWolf WC, Bruning CO, Morgentaler A
Immediate sexual rehabilitation by simultaneous placement of penile prosthesis in patients undergoing radical prostatectomy: initial results in 50 patients. Urology. 1997 Sep; 50(3):395-9.
Immediate sexual rehabilitation by simultaneous placement of penile prosthesis in patients undergoing radical prostatectomy: initial results in 50 patients.
Phleboliths in varicoceles presenting as spermatic cord mass. Fertil Steril. 2006 Jul; 86(1):219.e21-2.
Phleboliths in varicoceles presenting as spermatic cord mass.
Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006 Nov; 50(5):935-9.
Testosterone and prostate cancer: an historical perspective on a modern myth.
Wide variability in laboratory reference values for serum testosterone. J Sex Med. 2006 Nov; 3(6):1085-1089.
Wide variability in laboratory reference values for serum testosterone.
Testis and temperature: an historical, clinical, and research perspective. J Androl. 1999 Mar-Apr; 20(2):189-95.
Testis and temperature: an historical, clinical, and research perspective.
Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, McCullough A, Morgentaler A, Torres LO, Khera M
Sexual Rehabilitation After Treatment for Prostate Cancer-Part 1: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2017 Mar; 14(3):285-296.
Sexual Rehabilitation After Treatment for Prostate Cancer-Part 1: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Andrology: Testosterone reference ranges and diagnosis of testosterone deficiency. Nat Rev Urol. 2017 May; 14(5):263-264.
Andrology: Testosterone reference ranges and diagnosis of testosterone deficiency.
Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2017 Mar; 14(3):297-315.
Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Kritsas JJ, Schopperle WM, DeWolf WC, Morgentaler A
Rapid high resolution two-dimensional electrophoresis of human sperm proteins. Electrophoresis. 1992 Jul; 13(7):445-9.
Rapid high resolution two-dimensional electrophoresis of human sperm proteins.
Causality and association--more than just different shades of gray. Fertil Steril. 1997 Oct; 68(4):745.
Causality and association--more than just different shades of gray.
Journal of the American College of Surgeons
Part 2: Surgical palliation of advanced illness: what's new, what's helpful. J Am Coll Surg. 2005 Feb; 200(2):281-90.
Part 2: Surgical palliation of advanced illness: what's new, what's helpful.
Experimental cryptorchidism induces testicular germ cell apoptosis by p53-dependent and -independent pathways in mice. Biol Reprod. 1998 Feb; 58(2):492-6.
Experimental cryptorchidism induces testicular germ cell apoptosis by p53-dependent and -independent pathways in mice.
Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M
Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017 12; 72(6):1000-1011.
Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, Miner MM, Shabsigh R
The NERI Hypogonadism Screener: psychometric validation in male patients and controls. Clin Endocrinol (Oxf). 2011 Feb; 74(2):248-56.
The NERI Hypogonadism Screener: psychometric validation in male patients and controls.
Cultural biases and scientific squabbles: the challenges to acceptance of testosterone therapy as a mainstream medical treatment. Aging Male. 2007 Mar; 10(1):1-2.
Cultural biases and scientific squabbles: the challenges to acceptance of testosterone therapy as a mainstream medical treatment.
P53 and Fas are sequential mechanisms of testicular germ cell apoptosis. J Androl. 2002 Jan-Feb; 23(1):64-70.
P53 and Fas are sequential mechanisms of testicular germ cell apoptosis.
Apoptosis : an international journal on programmed cell death
Heat-induced testicular apoptosis occurs independently of hormonal depletion. Apoptosis. 1998 Sep; 3(4):281-7.
Heat-induced testicular apoptosis occurs independently of hormonal depletion.
Biochemical and biophysical research communications
p53 is associated with the nuclear envelope in mouse testis. Biochem Biophys Res Commun. 1997 Jun 27; 235(3):689-94.
p53 is associated with the nuclear envelope in mouse testis.
Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2009 Mar; 181(3):972-9.
Jannini EA, Gravina GL, Morgentaler A, Mortengaler A, Morales A, Incrocci L, Hellstrom WJ
Is testosterone a friend or a foe of the prostate? J Sex Med. 2011 Apr; 8(4):946-55.
Is testosterone a friend or a foe of the prostate?
Erectile dysfunction. J Long Term Eff Med Implants. 2003; 13(6):519-28.
A 66-year-old man with sexual dysfunction. JAMA. 2004 Jun 23; 291(24):2994-3003.
A 66-year-old man with sexual dysfunction.
Current diagnosis and management of impotence. Compr Ther. 1991 Jul; 17(7):25-30.
Current diagnosis and management of impotence.
Metastatic testicular teratoma invading the inferior vena cava. J Urol. 1988 Jul; 140(1):149-50.
Metastatic testicular teratoma invading the inferior vena cava.
Cady B, Barker F, Easson A, Aboulafia AJ, Ferson PF, Miner T, Morgentaler A
Part 3: surgical palliation of advanced illness: what's new, what's helpful. J Am Coll Surg. 2005 Mar; 200(3):457-66.
Part 3: surgical palliation of advanced illness: what's new, what's helpful.
Morgentaler A, Rhoden EL, Barqawi AB, Crawford ED
Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove. J Urol. 2006 Apr; 175(4):1572; author reply 1573-4.
Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove.
Motile organisms in the epididymis? Hum Reprod. 1998 Aug; 13(8):2335.
Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2007 May; 177(5):1954.
Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
Morgentaler A, Schopperle WM, Crocker RH, DeWolf WC
Protein differences between normal and oligospermic human sperm demonstrated by two-dimensional gel electrophoresis. Fertil Steril. 1990 Nov; 54(5):902-5.
Protein differences between normal and oligospermic human sperm demonstrated by two-dimensional gel electrophoresis.
Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med. 2007 May; 4(3):538-543.
Penile rehabilitation should become the norm for radical prostatectomy patients.
Testosterone and prostate safety. Front Horm Res. 2009; 37:197-203.
Should hypogonadal men with prostate cancer receive testosterone? J Urol. 2010 Oct; 184(4):1257-60.
Should hypogonadal men with prostate cancer receive testosterone?
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. Int J Impot Res. 2004 Feb; 16(1):95-7.
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole.
Effects of intracranial implantation of oestradiol and dihydrotestosterone on the sexual behaviour of the lizard Anolis carolinensis. J Endocrinol. 1979 Sep; 82(3):373-81.
Effects of intracranial implantation of oestradiol and dihydrotestosterone on the sexual behaviour of the lizard Anolis carolinensis.
Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med. 2010 Jan; 7(1 Pt 1):277-83.
Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
Testosterone therapy for men at risk for or with history of prostate cancer. Curr Treat Options Oncol. 2006 Sep; 7(5):363-9.
Testosterone therapy for men at risk for or with history of prostate cancer.
Yin Y, Hawkins KL, DeWolf WC, Morgentaler A
Heat stress causes testicular germ cell apoptosis in adult mice. J Androl. 1997 Mar-Apr; 18(2):159-65.
Heat stress causes testicular germ cell apoptosis in adult mice.
Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy. J Sex Med. 2012 Feb; 9(2):585-93.
Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy.
Lux M, Reyes-Vallejo L, Morgentaler A, Levine LA
Outcomes and satisfaction rates for the redesigned 2-piece penile prosthesis. J Urol. 2007 Jan; 177(1):262-6.
Outcomes and satisfaction rates for the redesigned 2-piece penile prosthesis.
Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer. J Sex Med. 2008 Aug; 5(8):1834-40.
Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer.
Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth. Eur Urol Focus. 2019 01; 5(1):81-89.
Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
Morgentaler A, Polzer P, Althof S, Bolyakov A, Donatucci C, Ni X, Patel AB, Basaria S
Delayed Ejaculation and Associated Complaints: Relationship to Ejaculation Times and Serum Testosterone Levels. J Sex Med. 2017 09; 14(9):1116-1124.
Delayed Ejaculation and Associated Complaints: Relationship to Ejaculation Times and Serum Testosterone Levels.
Serum Concentrations of Sex Hormone-binding Globulin Vary Widely in Younger and Older Men: Clinical Data from a Men's Health Practice. Eur Urol Focus. 2019 03; 5(2):273-279.
Serum Concentrations of Sex Hormone-binding Globulin Vary Widely in Younger and Older Men: Clinical Data from a Men's Health Practice.
Krakowsky Y, Conners W, Davidson E, Rawji A, Morgentaler A
Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States. Urology. 2017 Nov; 109:27-31.
Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States.
Rapidly shifting concepts regarding androgens and prostate cancer. ScientificWorldJournal. 2009 Jul 27; 9:685-90.
Rapidly shifting concepts regarding androgens and prostate cancer.
Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009 Dec 15; 101(12):1949-56.
Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.
Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M
Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010 Apr; 7(4 Pt 2):1627-56.
Endocrine aspects of male sexual dysfunctions.
Turning conventional wisdom upside-down: low serum testosterone and high-risk prostate cancer. Cancer. 2011 Sep 01; 117(17):3885-8.
Turning conventional wisdom upside-down: low serum testosterone and high-risk prostate cancer.
Ramsawh HJ, Morgentaler A, Covino N, Barlow DH, DeWolf WC
Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol. 2005 Oct; 174(4 Pt 1):1395-8.
Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy.
Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 2006 Mar-Apr; 18(2):201-5.
Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Hypogonadism in the man with erectile dysfunction: what to look for and when to treat. Curr Urol Rep. 2005 Nov; 6(6):476-81.
Hypogonadism in the man with erectile dysfunction: what to look for and when to treat.
Bruning CO, Breslin DS, Morgentaler A, Staskin DR
Experience with the penile prosthesis and artificial urinary sphincter. J Long Term Eff Med Implants. 1995; 5(1):27-45.
Experience with the penile prosthesis and artificial urinary sphincter.
Testosterone Therapy in a Man with Intermediate-risk Prostate Cancer: Pro. Eur Urol Focus. 2017 10; 3(4-5):316-318.
Testosterone Therapy in a Man with Intermediate-risk Prostate Cancer: Pro.
Treatment of an impacted fecalith with electrohydraulic lithotripsy. N Engl J Med. 1990 Mar 22; 322(12):855-6.
Treatment of an impacted fecalith with electrohydraulic lithotripsy.
Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009 Feb; 55(2):310-20.
Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med. 2009 Feb; 6(2):574-7.
Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer.
Lopez DS, Qiu X, Advani S, Tsilidis KK, Khera M, Kim J, Morgentaler A, Wang R, Canfield S
Double trouble: Co-occurrence of testosterone deficiency and body fatness associated with all-cause mortality in US men. Clin Endocrinol (Oxf). 2018 Jan; 88(1):58-65.
Double trouble: Co-occurrence of testosterone deficiency and body fatness associated with all-cause mortality in US men.
The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol. 2008 May; 179(5):1741-4.
The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency. J Sex Med. 2012 Jun; 9(6):1681-96.
Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency.
Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004 Jan 29; 350(5):482-92.
Risks of testosterone-replacement therapy and recommendations for monitoring.
Management of the impacted ureteral calculus. J Urol. 1990 Feb; 143(2):263-6.
Management of the impacted ureteral calculus.
Morgentaler A, Barada J, Niederberger C, Donatucci C, Garcia CS, Natanegara F, Ahuja S, Wong DG
Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design. J Sex Med. 2006 May; 3(3):492-503.
Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design.
Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000 Mar; 163(3):824-7.
Is low serum free testosterone a marker for high grade prostate cancer?
Ho GT, Gardner H, Mostofi K, DeWolf WC, Loughlin KR, Morgentaler A
The effect of testicular nongerm cell tumors on local spermatogenesis. Fertil Steril. 1994 Jul; 62(1):162-6.
The effect of testicular nongerm cell tumors on local spermatogenesis.
Glina S, Rivero MA, Morales A, Morgentaler A
Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges. J Sex Med. 2010 Feb; 7(2 Pt 1):640-4.
Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges.
New concepts regarding the relationship of testosterone and prostate cancer. Future Oncol. 2007 Apr; 3(2):123-6.
New concepts regarding the relationship of testosterone and prostate cancer.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Does testosterone therapy increase the risk of prostate cancer? Endocr Pract. 2008 Oct; 14(7):904-11.
Does testosterone therapy increase the risk of prostate cancer?
Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, Morgentaler A, Miner MM
Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls. Aging Male. 2009 Jun-Sep; 12(2-3):77-85.
Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and controls.
Testosterone replacement therapy and prostate cancer. Urol Clin North Am. 2007 Nov; 34(4):555-63, vii.
Testosterone replacement therapy and prostate cancer.
Words of wisdom. Re: Adverse events associated with testosterone administration. Eur Urol. 2011 Mar; 59(3):465.
Words of wisdom. Re: Adverse events associated with testosterone administration.
Brown LF, Yeo KT, Berse B, Morgentaler A, Dvorak HF, Rosen S
Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol. 1995 Aug; 154(2 Pt 1):576-9.
Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen.
McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA
A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion. J Sex Med. 2012 Feb; 9(2):594-601.
A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion.
Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996 Dec 18; 276(23):1904-6.
Occult prostate cancer in men with low serum testosterone levels.
Congenital anomalies of the vas deferens, epididymis, and seminal vesicles. Urology. 1997 Mar; 49(3):313-21.
Congenital anomalies of the vas deferens, epididymis, and seminal vesicles.
Rhoden EL, Estrada C, Levine L, Morgentaler A
The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol. 2003 Sep; 170(3):795-8.
The value of pituitary magnetic resonance imaging in men with hypogonadism.
Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J Urol. 2001 Sep; 166(3):932-7.
Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study.
Partial duplication of the vas deferens. J Urol. 1998 Mar; 159(3):988-9.
Partial duplication of the vas deferens.